Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label crossover PK and efficacy bridging study of oral ASTX727 versus injectable decitabine in Chinese patients with myelodysplastic syndrome
CTR20233084Phase 2Active
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inqovi in myelodysplastic syndrome (MDS) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Complete remission rate and Cumulative 5-day decitabine exposure (AUC0-τ). Started Oct 2023; status: active.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20233084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233084.